Prof. Dr. Markus Diefenbacher

Group Leader

Prof. Dr. Markus Diefenbacher

“Like all cancer researchers, I want to tear off the cloak of invisibility from tumor cells. In doing this, I am enthusiastic about building bridges, about collaboration across scientific disciplines, methods or people!”

 Visit the Diefenbacher Lab  

Academic Career and Research Areas

Prof. Markus Diefenbacher brings a fascinating perspective to the study of the interaction between tumors and the immune system. He is fascinated by the genetic complexity of tumors, especially solid tumors. His research goals include deciphering the genetic complexity of tumors and developing innovative therapeutic approaches against lung cancer. Here it is, above all, the rapid development of new methods for imaging and analyzing complex biological processes that excites him. 

Especially in the early days of his research at KIT, he was grateful for good mentors who encouraged his enthusiasm and ambition for science. His time abroad was also very formative, especially the work at Cancer Research UK (CRUK, now The Francis Crick Institute) in London and the exchange with world-leading scientists. In this period, he focused on two cancer entities, lung and colorectal cancer, and by using complex mouse genetics, significantly contributed to merging the fields of basic ubiquitin biology and cancer research. He then joined the Department of Biochemistry and Molecular Biology at the Biocenter of the University of Würzburg and started his first independent lab. 

In 2023 he moved with his lab to Munich (Institute of Lung Health and Immunity, Helmholtz Munich) and focused on the development of novel murine models of solid tumours, especially lung- and intestinal cancer, by using virally encapsulated delivery of CRISPR components to epithelial cells, resulting in building the foundation of current internationally visible collaborations.

 

Fields of Work and Expertise

CRISPR surrogate models imaging spatial biology Oncology

multi-omics

Professional Background

Since 2025

Initiator and organizer of the annual “Building Bridges in Munich Cancer Research” Workshop

Since 2024

Investigator at Deutsches Konsortium für Translationale Krebsforschung (DKTK)

Since 2023

PI of the research group "Experimental Immuno-Oncology" at LHI/Helmholtz Munich and Professor of Experimental Pneumology at the LMU clinic Munich

2015 - 2023

Junior group leader in Würzburg at the Biocenter, Chair of Biochemistry and Molecular Biology

2009 - 2015

CRUK // Cancer Research UK Lincolns Inn Fields Research Institute (CRUK LRI), Holborn, London, UK

2004 -2009

Diploma thesis with subsequent PhD at Helmholtz Zentrum Karlsruhe (now KIT Campus Nord), Institute of Toxicology and Genetics, in the group of Peter Herrlich & Olivier Kassel

1997 - 2004

Diploma Biology studies at the Karlsruhe Institute of Technology (KIT), Karlsruhe.

Publications

J. Clin. Invest. 135:e180927 (2025)

Kumari, N. ; Wright, S.C. ; Witham, C.M. ; Monserrat, L. ; Palafox, M. ; Charles Richard, J.L. ; Costa, C. ; Elkabets, M. ; Agostino, M. ; Klemm, T. ; Eccles, M.K. ; Garnham, A. ; Wu, T. ; Nilsson, J.A. ; Walz, N. ; Venugopal, V. ; Cerra, A. ; Vasilevski, N. ; Bridgeman, S.C. ; Bassi, S. ; Saei, A. ; Helal, M. ; Neundorf, P. ; Riedel, A. ; Rosenfeldt, M. ; Gill, J. ; Pahor, N. ; Hartmann, O. ; Chung, J. ; Sidhu, S.S. ; Moderau, N. ; Jha, S. ; Rodon, J. ; Diefenbacher, M. ; Komander, D. ; Serra, V. ; Eichhorn, P.

USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer.
Cell Death Differ., DOI: 10.1038/s41418-025-01565-w (2025)

Suanes-Cobos, L. ; Aguilera-Ventura, I. ; Torres-Ramos, M. ; Serrano-Yubero, A. ; Moreno Fernández-Aliseda, C. ; Fernández, S. ; Garrido-Rodríguez, M. ; de la Luna, S. ; Prieto-Garcia, C. ; Diefenbacher, M. ; Mejias-Perez, E. ; Calzado, M.A.

A novel feedback loop between DYRK2 and USP28 regulates cancer homeostasis and DNA damage signaling.
Oncogene 44:336 (2025)

Reissland, M. ; Hartmann, O. ; Tauch, S. ; Bugter, J.M. ; Prieto-Garcia, C. ; Schulte, C. ; Loebbert, S. ; Solvie, D. ; Bitman-Lotan, E. ; Narain, A. ; Jacomin, A.C. ; Schuelein-Voelk, C. ; Fuss, C.T. ; Pahor, N. ; Ade, C. ; Buck, V. ; Potente, M. ; Li, V. ; Beliu, G. ; Wiegering, A. ; Grossmann, T. ; Eilers, M. ; Wolf, E. ; Maric, H. ; Rosenfeldt, M. ; Maurice, M.M. ; Dikic, I. ; Gallant, P. ; Orian, A. ; Diefenbacher, M.

Correction: USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer.
Redox Biol. 80:103503 (2025)

Li, H. ; Furusawa, T. ; Cavero, R. ; Xiao, Y. ; Chari, R. ; Wu, X. ; Sun, D. ; Hartmann, O. ; Dhall, A. ; Holewinski, R. ; Andresson, T. ; Karim, B. ; Villamor-Payà, M. ; Gallardo, D. ; Day, C.P. ; Pal, L.R. ; Nair, N.U. ; Ruppin, E. ; Aladjem, M.I. ; Pommier, Y. ; Diefenbacher, M. ; Lim, J.M. ; Levine, R.L. ; Stracker, T.H. ; Weyemi, U.

Metabolic dependency mapping identifies Peroxiredoxin 1 as a driver of resistance to ATM inhibition.
Nat. Commun. 15:10138 (2024)

Yang, L. ; Liu, Q. ; Kumar, P. ; Sengupta, A. ; Farnoud, A. ; Shen, R. ; Trofimova, D. ; Ziegler, S. ; Davoudi, N. ; Doryab, A. ; Yildirim, A.Ö. ; Diefenbacher, M. ; Schiller, H. B. ; Razansky, D. ; Piraud, M. ; Burgstaller, G. ; Kreyling, W.G. ; Isensee, F. ; Rehberg, M. ; Stöger, T. ; Schmid, O.

LungVis 1.0: An automatic AI-powered 3D imaging ecosystem unveils spatial profiling of nanoparticle delivery and acinar migration of lung macrophages.
Oncogene, DOI: 10.1038/s41388-024-03141-x (2024)

Reissland, M. ; Hartmann, O. ; Tauch, S. ; Bugter, J.M. ; Prieto-Garcia, C. ; Schulte, C. ; Loebbert, S. ; Solvie, D. ; Bitman-Lotan, E. ; Narain, A. ; Jacomin, A.C. ; Schuelein-Voelk, C. ; Fuss, C.T. ; Pahor, N. ; Ade, C. ; Buck, V. ; Potente, M. ; Li, V. ; Beliu, G. ; Wiegering, A. ; Grossmann, T. ; Eilers, M. ; Wolf, E. ; Maric, H. ; Rosenfeldt, M. ; Maurice, M.M. ; Dikic, I. ; Gallant, P. ; Orian, A. ; Diefenbacher, M.

USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer.
Mol. Carcinog. 63, 1024-1037 (2024)

Furusawa, T. ; Cavero, R. ; Liu, Y. ; Li, H. ; Xu, X. ; Andresson, T. ; Reinhold, W.C. ; White, O. ; Boufraqech, M. ; Meyer, T.J. ; Hartmann, O. ; Diefenbacher, M. ; Pommier, Y. ; Weyemi, U.

Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer.
Apoptosis 29, 1145-1160 (2024)

Abbas, R. ; Hartmann, O. ; Asiss, D.T. ; Abbas, R. ; Kagan, J. ; Kim, H.T. ; Oren, M. ; Diefenbacher, M. ; Orian, A. ; Larisch, S.

ARTS and small-molecule ARTS mimetics upregulate p53 levels by promoting the degradation of XIAP.